Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program
- PMID: 33586169
- DOI: 10.1002/ijc.33513
Declining rates of cervical intraepithelial neoplasia in British Columbia, Canada: An ecological analysis on the effects of the school-based human papillomavirus vaccination program
Abstract
Since 2008, girls in British Columbia (BC), Canada, have been offered HPV vaccination through a school-based, publicly funded immunization program. The oldest birth cohort eligible for the vaccination program was born in 1994 and uptake is on average 63%. To evaluate the impact of the HPV vaccine in BC, ecological trends in cervical intraepithelial neoplasia (CIN) rates were assessed in young women before and after the implementation of the HPV vaccination program. Information on all Pap smears and histopathological abnormalities, in calendar years 2004-2017 in women 16-28 years of age in BC were obtained from the population-based BC Cancer Cervix Screening Program database. Rates of CIN 2 and 3 were calculated as the number of cases divided by the number of cytology specimens for that period. Rate ratios (RR) were calculated by negative binomial piecewise regression. Age-centered incidence rates of CIN 2 and 3 in BC declined significantly among women 16-23 years of age after HPV vaccine introduction compared to before vaccine introduction. The overall reduction postvaccination for CIN2 and 3 in women 16-23 years was respectively 62% (95% CI 54-68%) and 65% (95% CI 58-71%). Age-specific rates for CIN2 significantly declined for those 18-22 years of age and for those 19, 20 and 23 years of age for CIN3. Among women 24-28 years of age no decline in CIN2 and 3 rate over time was observed. The observed reduction in CIN 2 and 3 rates since the introduction of the school-based HPV vaccine program might illustrate the population impact of the BC provincial school-based HPV vaccination program.
Keywords: cervical intraepithelial neoplasia; immunization programs; papillomavirus vaccines; prevention.
© 2021 UICC.
Similar articles
-
Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.Int J Cancer. 2015 Oct 15;137(8):1931-7. doi: 10.1002/ijc.29508. Epub 2015 Jun 3. Int J Cancer. 2015. PMID: 25754686
-
Cervical Intraepithelial Neoplasia Rates in British Columbia Women: A Population-Level Data Linkage Evaluation of the School-Based HPV Immunization Program.J Infect Dis. 2020 Jan 1;221(1):81-90. doi: 10.1093/infdis/jiz422. J Infect Dis. 2020. PMID: 31504649 Free PMC article.
-
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.Lancet. 2019 Aug 10;394(10197):497-509. doi: 10.1016/S0140-6736(19)30298-3. Epub 2019 Jun 26. Lancet. 2019. PMID: 31255301 Free PMC article.
-
Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.BMJ Open. 2017 Aug 18;7(8):e015867. doi: 10.1136/bmjopen-2017-015867. BMJ Open. 2017. PMID: 28821519 Free PMC article. Clinical Trial.
-
Human papillomavirus vaccines versus cervical cancer screening.Clin Oncol (R Coll Radiol). 2008 Aug;20(6):388-94. doi: 10.1016/j.clon.2008.04.006. Epub 2008 Jun 5. Clin Oncol (R Coll Radiol). 2008. PMID: 18538554 Review.
Cited by
-
Canadian Guideline on the Management of a Positive Human Papillomavirus Test and Guidance for Specific Populations.Curr Oncol. 2023 Jun 9;30(6):5652-5679. doi: 10.3390/curroncol30060425. Curr Oncol. 2023. PMID: 37366908 Free PMC article.
-
Impact of human papillomavirus vaccines in the reduction of infection, precursor lesions, and cervical cancer: A systematic literature review.Hum Vaccin Immunother. 2025 Dec;21(1):2497608. doi: 10.1080/21645515.2025.2497608. Epub 2025 Jun 9. Hum Vaccin Immunother. 2025. PMID: 40485552 Free PMC article. Review.
References
REFERENCES
-
- Syrjänen K, Hakama M, Saarikoski S, et al. Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population. Sex Transm Dis. 1990;17(1):15-19.
-
- de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer. 2017;141(4):664-670. https://doi.org/10.1002/ijc.30716.
-
- LaMontagne DS, Bloem PJN, Brotherton JML, Gallagher KE, Badiane O, Ndiaye C. Progress in HPV vaccination in low- and lower-middle-income countries. Int J Gynecol Obstet. 2017;138:7-14. https://doi.org/10.1002/ijgo.12186.
-
- Altobelli E, Rapacchietta L, Profeta VF, Fagnano R. HPV-vaccination and cancer cervical screening in 53 WHO European countries: an update on prevention programs according to income level. Cancer Med. 2019;8(5):2524-2534. https://doi.org/10.1002/cam4.2048.
-
- Pouyanfard S, Müller M. Human papillomavirus first and second generation vaccines-current status and future directions. Biol Chem. 2017;398(8):871-889. https://doi.org/10.1515/hsz-2017-0105.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials